Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds the benefits of bisphosphonates for bone metastases pain represents a potentially lucrative marketing target.

"We found that pain specialists do not consider bisphosphonates to be part of their treatment methodology," said Mary Fletcher-Louis, analyst at Decision Resources. "Accordingly, education of pain specialists concerning the benefits of bisphosphonates as a treatment option for metastases-related pain could lead to significant growth in the bisphosphonate market."

Additionally, clinicians reported that RANK-ligand inhibitors are an important novel class in development for pain caused by bone metastases. Amgen's AMG-162, currently in Phase II trials, holds the potential to achieve gains in pain control among patients with bone metastases.

RANK-ligand inhibitors, which will launch for bone pain toward the end of 2013, will be used in addition to bisphosphonates and strong narcotics to achieve a dose-sparing effect and additive analgesia, rather than replacing these classes.

About Bone Metastases Pain

Bone metastases, secondary cancers in the bone, are a common phenomenon of advanced cancer. They are the most common cause of the debilitating pain that occurs in many patients with advanced malignancies. Bone metastases are particularly prevalent in prostate cancer, breast cancer, and multiple myeloma, occurring in up to 85% of metastatic patients with these tumor types.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Single-Pill Combinations Accounted For Approximately 10% of the Type 2 Diabetes Drug Market in 2003

View Now